What are my alternatives to knee replacement?
Compare nonsurgical knee arthritis care, injection choices, and selected surgical alternatives—with evidence, limits, and questions for your clinician.
Read the guide ↗Medically reviewed by Charles A. DeCook, MD ·
← All optionsLearn about the evidence
Unapproved “healing” peptides
Not another rung. Not an alternative to replacement.
THE SHORT VERSION · 30 SECONDS
What should I know about peptides?
Different products. Different evidence.
Silent visual explainer · captions included
Read the explanation
- Peptide describes a type of molecule, not a treatment promise.
- Prescription weight medicines and products marketed for healing are different.
- Evidence and approval are specific to each product and use.
- Review medicines and supplements with your clinician, especially around surgery.
Who might it suit?
For: Understanding BPC-157, TB-500, KPV, MOTS-c, GHK-Cu, and “Wolverine stack” claims.
Not for: Joint repair or post-operative recovery products on this platform.
Limits and important cautions
A peptide stack, research label, or testimonial does not establish a safe effective regimen. Approved weight-management medicines have a different evidence base.
What happens, how long, and what could it cost?
- What happens
- Clarify the exact ingredient, route, regulatory status, and evidence before considering a provider offer.
- When might I notice a change?
- A reliable personal timeline cannot be predicted from the evidence reviewed here. Agree on a review date before starting.
- How long might benefit last?
- Benefit and durability depend on the exact intervention and population. The evidence section below explains what is known.
- Repeat treatment
- No established joint-healing regimen is endorsed here.
- Activity and recovery
- Ask who provides follow-up, what symptoms need urgent attention, and what restrictions apply to you.
- Ask for a complete estimate
- Ask for the full product and monitoring cost; price does not establish effectiveness.
Use this as a consultation guide. A timeline is not a guarantee; the evidence and FDA sections below remain part of the decision.
THE EVIDENCE IN CONTEXT
Predominantly preclinical evidence
Read the 3 selected references
- Emerging BPC-157 use in orthopaedic sports medicine ↗
Evidence is predominantly preclinical, with very limited human musculoskeletal data. Animal healing findings do not establish an effective human regimen.
- Peptide supplements in sports medicine ↗
Most studies were preclinical; available human studies did not substantiate broad recovery claims. Findings for one compound do not establish safety for another.
- FDA: compounding substances with safety concerns ↗
Ingredient- and route-specific information for BPC-157, thymosin beta-4 fragment, KPV, MOTS-c, and injectable GHK-Cu; not proof of clinical benefit.
FDA status
Not approved for OA or joint recoveryBPC-157, TB-500, KPV, MOTS-c, and injectable GHK-Cu are not FDA-approved treatments for osteoarthritis or joint-replacement recovery. FDA identifies safety uncertainties for these compounding substances. A committee discussion, pharmacy license, or compounded formulation is not FDA drug approval.
Site summary of FDA information · reviewed September 19, 2026. Refer to current product labeling. This is not an FDA endorsement of this site.What do professional guidelines say?
ACR: No recommendation for these OA treatments.
Will Medicare cover it?
No OA coverage.